Welcome To The Official Website of NeoCare Inc
NeoCare Inc. founded in 2021 is developing non-invasive techniques disease detection in new born in a cost-effective manner.
Problem Statement: Neonatal jaundice, anemia and hypoxia are the most common health issues encountered by newborns globally and constitute a major percentage of infant mortality. The prevalence of neonatal jaundice anemia and hypoxia is quoted to be between 50% and 60% among healthy term neonates. Similarly, 42% babies born are affected with anemia. Additionally, 1.4 million neo-natal deaths are attributed to hypoxia and oxygen deficiency related disorders. According to World Health Organization (WHO), the above-mentioned child mortality is preventable in nature if constant monitoring is invoked. Conventionally, invasive blood test procedures are used repeatedly for diagnosis and prognosis of the medical ailments.
This provides painful and stressed experience to the new born and the parents. The medical fraternity experiences significant delay in obtaining laboratory test results owing to laboratory test procedures. The hospitals have also to maintain bulky benchtop equipment and trained scientific manpower and hence which adds to significant capital investment.
Product: Samira provides painless, instantaneous and stress-free solution to the new born/parents for determination anemia, jaundice and hypoxia unlike conventional methods involving multiple needle pricks at an affordable cost.
Publications and IP protection: The underlying technology has resulted in five peer reviewed journal publications. The US provisional patent has been filed.
Competitive landscape: Samira introduces competition to conventional blood test providing stress free solution to the users and parents. Some non-invasive transcutaneous bilirubin devices pose competition to the SAMIRA device. However, multiple parameter capability and IoT capability for EHR and prognosis of the patient provides a clear edge on the competition.
Team: The team comprises extremely bright scientists and medical doctors to cater for individual departments of the project.
Soumendra Singh He received his PhD and M.Tech degree from the University of Calcutta in Computer Science and Application. His research interests include exploration of spectroscopic techniques in environmental as well as bio-medical instrumentation and high frequency microwave propagation study. He received Gandhian Young Technological Innovation (GYTI) Award 2017 from Rashtrapati Bhavan (House of the President, Republic of India), New Delhi. He is the face of NeoCare and is actively involved in design and engineering aspects of ASAMIR device. He has more than 14 years of experience in designing bio-medical instrumentation. He has participated prominently in many projects that resulted in few products which have been commercialized by other companies. He is the CEO of NeoCare
Market opportunity: Assuming 3.6 million babies born in the United States and 80% of them need blood tests for some reason, 24 million tests need to be performed annually. NeoCare charges 7.5 CAD in comparison to 15 CAD for three conventional tests, total market opportunity is 181 million annually. Obtainable market share can be estimated to be 50 million. Thus, global obtainable market opportunity can be estimated to 151 million.
Additional product road map: NeoCare also offers a product of detecting Urinary bladder cancer from unprocessed urine samples at point of care. The functional prototype is ready with a clinical trial of 100 patients.